AGN 0.65% 77.0¢ argenica therapeutics limited

Brilliant. Reached the 23 patient milestone. Review of Safety...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 9,897 Posts.
    lightbulb Created with Sketch. 989
    Brilliant. Reached the 23 patient milestone. Review of Safety data triggered.

    3 patients in a week since the last update with only 5 of the activated sites.

    With 10 activated sites this trial will be over well before the 18 month time line.

    Patient permission is no problem/hinderence. Who wouldn't want to say "yes please ! " given the safety data.

    Also while the trial is progressing at pace we have :

    "In parallel, the Company is investigating the potential utility of ARG-007 in other neurological
    conditions. Underpinning this research, over $4 million in non-dilutive grant and philanthropic
    funding has been secured throughout the life of the projects from the Federal and Western
    Australian governments, the Stan Perron Charitable Foundation, the McCusker Foundation,
    and donors to the Perron Institute."

    Traumatic Brain Injury, Alzheimers and HIE all getting prepped for Phase 2 trials non dilutive funded by others.
 
watchlist Created with Sketch. Add AGN (ASX) to my watchlist
(20min delay)
Last
77.0¢
Change
-0.005(0.65%)
Mkt cap ! $98.63M
Open High Low Value Volume
77.5¢ 80.0¢ 77.0¢ $149.1K 190.7K

Buyers (Bids)

No. Vol. Price($)
1 2820 77.0¢
 

Sellers (Offers)

Price($) Vol. No.
77.5¢ 2824 1
View Market Depth
Last trade - 16.10pm 12/11/2024 (20 minute delay) ?
AGN (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.